Summary & Overview
HCPCS G9499: Hepatitis C, No Antiviral Treatment Documented
HCPCS Level II code G9499 is a quality-measure documentation code used to indicate that a patient with hepatitis C did not start or is not receiving antiviral treatment during the measurement period. The code facilitates tracking of treatment gaps and care quality related to hepatitis C management at a national level, supporting reporting and performance measurement across payers and programs. National attention on hepatitis C treatment uptake and elimination efforts makes documentation of untreated patients relevant for clinical quality improvement, population health management, and pay-for-performance programs.
This analysis covers major national payers including Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find a concise explanation of the code’s clinical meaning and service context, an outline of typical sites where the code is recorded, and what the code signals for care measurement. The publication also summarizes benchmarks and policy considerations relevant to hepatitis C treatment documentation and describes how G9499 fits into broader quality reporting frameworks. Data not provided in the input (such as common modifiers, associated taxonomies, specific ICD-10 pairings, and related codes) is noted as unavailable in the source material and is not inferred.
Billing Code Overview
HCPCS Level II code G9499 indicates that the patient did not start or is not receiving antiviral treatment for hepatitis C during the measurement period. This code documents lack of antiviral therapy for hepatitis C infection as measured within a defined reporting or quality measurement period.
-
Service type: Quality measure documentation related to hepatitis C antiviral treatment status
-
Typical site of service: Outpatient clinic or ambulatory care setting where hepatitis C diagnosis and treatment decisions are managed
Clinical & Coding Specifications
Clinical Context
A typical patient scenario involves an adult with confirmed chronic hepatitis C virus (HCV) infection who, during the measurement period, has not been started on direct-acting antiviral therapy. The patient may have been diagnosed in primary care, an infectious disease clinic, or a community health setting. The clinical workflow begins with diagnosis documentation (HCV antibody and RNA), assessment of liver disease severity (laboratory tests, transient elastography or imaging), review of comorbidities and potential drug interactions, and counseling regarding antiviral therapy. Despite indicated treatment, therapy initiation did not occur during the measurement period due to factors such as patient refusal, loss to follow-up, access barriers, untreated substance use without linkage to treatment, insurance authorization delays, or clinical contraindications documented by the clinician. Typical sites of service include outpatient primary care clinics, infectious disease/hepatology specialty clinics, community health centers, and hospital outpatient departments. The service type is a clinical quality measurement/event documenting lack of antiviral treatment initiation for hepatitis C during a defined measurement period.
Coding Specifications
| Modifier | Description | When to Use |
|---|---|---|
25 | Significant, separately identifiable evaluation and management service by the same physician on the same day of the procedure | When an E/M visit is provided on the same day as a procedure or service related to HCV evaluation and must be reported separately |